| Variable | HPV+ (Arm A) | HPV− (Arm B) |
| Tumour (T) |
|
|
| T1 | 23.5% | 12.5% |
| T2 | 35.3% | 25% |
| T3 | 29.4% | 41.7% |
| T4 | 11.7% | 20.8% |
| Node (N) |
|
|
| N0 | 5.9% | 18.8% |
| N1 | 17.6% | 43.8% |
| N2 | 23.5% | 22.9% |
| N3 | 52.9% | 14.6% |
| Composite stage |
|
|
| Stage III | 29.4% | 56.3% |
| Stage IV | 70.6% | 43.8 |
| Sub sites |
|
|
| Tonsil | 52.9% | 45.8% |
| BOT | 29.4% | 25.0% |
| Palate | 11.8% | 16.7% |
| Vallecula | 5.9% | 12.5% |
| Pathological subtypes |
|
|
| Well differentiated SCC | 11.8% | 14.6% |
| Moderately differentiated SCC | 47.1% | 64.6% |
| Poorly differentiated SCC | 23.5% | 18.8% |
| Basaloid differentiation SCC | 11.8% | 0 |
| Unknown differentiation SCC | 5.9% | 2.1% |